Preliminary results from TOPAZ-III, a phase 3b study evaluating the efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin in naive or experienced adults in Brazil with HCV genotype 1 infection and advanced fibrosis/cirrhosis
Mario G. Pessoa José Valdez Madruga Ramalho; Katia Alves; Daniel E Cohen; Estevao Portela Nunes; Hugo Cheinquer; Carlos E Brandão-Mello; Maria Cássia Jacintho Mendes-Côrrea; Maria Lucia G Ferraz; Sara Lari; Li Lui; Rakesh Tripathi; Tami Pilot-Matias; Nancy Schulman; Ana de Lourdes Candolo Martinelli; Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (67. 2016 Boston)
Hepatology Baltimore v. 64, suppl. S1, p. 949A-950A, res. 1919, 2016
Baltimore 2016
Localização:
FMRP - Fac. Medicina de Ribeirão Preto
(pcd 2871656 Estantes Deslizantes )(Acessar)
High rate of sustained response after consensus interferon (CIFN) plus ribavirin (RB) in chronic hepatitis C patients previously resistant to combined theraphy (IFN+RB)
Luiz C. da Silva Leda C Bassit; Suzane K. Ono Nita; Ana Nishiya; Carmem L Madruga; Flair Jose Carrilho; Annual Meeting the American Association (52. 2001 Dallas)
Hepatology Philadelphia v. 34, n. 4, pt. 2 of 2, outubro, p. 586A, res. 1658, 2001
Philadelphia 2001
Item não circula. Consulte sua biblioteca.(Acessar)